secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001193125-24-049263
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma FY2023 net loss $176.9M; cash $340.5M; expects Phase 3 readouts in 2024
--------------------------------------------------------------------------------

- FY2023 net loss of $176.9M ($2.15 per share) vs $11.5M loss prior year; revenue fell to $14.1M from $102.7M.
- Cash at Dec 31, 2023: $340.5M; proforma cash after Feb 2024 $202M upsized offering ~$500M.
- Phase 3 BROOKLYN topline in HeFH expected 3Q2024; BROADWAY in ASCVD expected 4Q2024.
- PREVAIL CVOT enrollment to complete 1Q2024; topline data expected 2026. TANDEM FDC trial initiation 1Q2024 with data 1Q2025.
- Appointed William H. Lewis as Board Chair; Phase 2 data showed significant LDL-C lowering with placebo-like safety.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/0001193125-24-049263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524049263/d772021d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-049263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer